Dr Amol Akhade (@suyogcancer) 's Twitter Profile
Dr Amol Akhade

@suyogcancer

Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists

ID: 1135941148378247168

linkhttp://suyogcancerclincs.com calendar_today04-06-2019 16:07:29

6,6K Tweet

3,3K Takipçi

125 Takip Edilen

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo
Dr Amol Akhade
@suyogcancer

a month ago

What's new and exciting data coming up at #WLCC24 . 1- Perioperative vs Neoadjuvant Nivo. Patient level data analysis. 2- Osimertinib with or without Savolitinib for met aberrant EGFR mutated 1st line NSCLC 3 - Aumolertinib maintenance after CTRT for stage 3 NSCLC ( polestar )

What's new and exciting data coming up at #WLCC24 . 1- Perioperative vs Neoadjuvant Nivo. Patient level data analysis. 2- Osimertinib with or without Savolitinib for met aberrant EGFR mutated 1st line NSCLC 3 - Aumolertinib maintenance after CTRT for stage 3 NSCLC ( polestar )